National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

satraplatin
An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Orplatna
Code names:BMS-182751
BMY-45594
JM216
Chemical structure names:
  • (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
  • (OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum
  • platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43)



Previous:SarCNU, sargramostim, sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant, sargramostim plasmid DNA melanoma vaccine adjuvant, sargramostim plasmid DNA pancreatic tumor cell vaccine
Next:Satric, SB-743921, SB-AS02B adjuvant, SB-AS15 adjuvant, SC-PEG E. coli L-asparaginase

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov